Introduction and Objectives: The aim of this study was to assess if there is a difference in survival after radical cystectomy (RC) when examined in relation to prior non-muscle invasive bladder cancer (NMIBC) disease vs. invasive cancer de novo at time of diagnosis. Methods: We conducted a retrospective study of all patients who underwent RC within Quebec health insurance medical services database during the years (2000-2009). Overall survival (OS) outcome was assessed with Kaplan-Meier curves and hazard ratios (HRs) adjusted for age and gender. Results: A total of 2,671 subjects met the eligibility criteria. Among them, 19.8% had presumed prior NMIBC that further progressed to invasive disease. Median survival after RC for patients with presumed prior NMIBC was 4.3 years as compared to patients with presumed invasive disease de novo 3.7 years (p = 0.007, Wilcoxon test). Patients with presumed NMIBC at the time of diagnosis had a 16% decrease in the risk of mortality after RC, when compared to patients with presumed invasive BC de novo (HR 0.84, 95% CI 0.73-0.96 (p = 0.0166)). Conclusion: Our results suggest a slightly better prognosis, regarding OS after RC for patients with presumed NMIBC who progressed to invasive disease, when compared to patients with presumed invasive disease de novo at the time of diagnosis.

Keywords:
Radical cystectomy, Non-muscle invasive bladder cancer, Survival, Quebec, De novo, Progressive
1.
Mossanen M, Gore JL: The burden of bladder cancer care: direct and indirect costs. Curr Opin Urol 2014;24:487-491.
2.
Canadian Cancer Society's Advisory Committee on Cancer Statistics. Canadian Cancer Statistics 2014. Toronto, Canadian Cancer Society, 2014.
3.
Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al: Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466-475; discussion 475-477.
4.
Aziz A, Gierth M, Fritsche HM, May M, Otto W, Denzinger S, et al: Oncological outcome of primary versus secondary muscle-invasive bladder cancer is comparable after radical cystectomy. Urol Int 2013;91:97-102.
5.
de Vries RR, Nieuwenhuijzen JA, Vincent A, van Tinteren H, Horenblas S: Survival after cystectomy for invasive bladder cancer. Eur J Surg Oncol 2010;36:292-297.
6.
Ferreira U, Matheus WE, Nardi Pedro R, Levi D'Ancona CA, Reis LO, Stopiglia RM, et al: Primary invasive versus progressive invasive transitional cell bladder cancer: multicentric study of overall survival rate. Urol Int 2007;79:200-203.
7.
May M, Braun KP, Richter W, Helke C, Vogler H, Hoschke B, Siegsmund M: [Radical cystectomy in the treatment of bladder cancer always in due time?]. Urologe A 2007;46:913-919.
8.
Türkölmez K, Tokgöz H, Reşorlu B, Köse K, Bedük Y: Muscle-invasive bladder cancer: predictive factors and prognostic difference between primary and progressive tumors. Urology 2007;70:477-481.
9.
Lee CT, Dunn RL, Ingold C, Montie JE, Wood DP Jr: Early-stage bladder cancer surveillance does not improve survival if high-risk patients are permitted to progress to muscle invasion. Urology 2007;69:1068-1072.
10.
May M, Helke C, Nitzke T, Vogler H, Hoschke B: Survival rates after radical cystectomy according to tumor stage of bladder carcinoma at first presentation. Urol Int 2004;72:103-111.
11.
Yiou R, Patard JJ, Benhard H, Abbou CC, Chopin D: Outcome of radical cystectomy for bladder cancer according to the disease type at presentation. BJU Int 2002;89:374-378.
12.
Hidas G, Pode D, Shapiro A, Katz R, Appelbaum L, Pizov G, et al: The natural history of secondary muscle-invasive bladder cancer. BMC Urol 2013;13:23.
13.
Kotb AF, Kovac E, Kassouf W, Chin J, Fradet Y, Izawa J, et al: Radical cystectomy for clinically muscle invasive bladder cancer: does prior non-invasive disease affect clinical outcomes? World J Urol 2012;30:761-767.
14.
Vaidya A, Soloway MS, Hawke C, Tiguert R, Civantos F: De novo muscle invasive bladder cancer: is there a change in trend? J Urol 2001;165:47-50; discussion 50.
15.
Schrier BP, Hollander MP, van Rhijn BW, Kiemeney LA, Witjes JA: Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur Urol 2004;45:292-296.
16.
Hornák M, Bárdos A: [Biologic characteristics of invasive bladder cancer: is there a difference between primary and progressive tumours?]. Rozhl Chir 2004;83:648-650.
17.
Zakaria AS, Santos F, Dragomir A, Tanguay S, Kassouf W, Aprikian AG: Postoperative mortality and complications after radical cystectomy for bladder cancer in Quebec: a population-based analysis during the years 2000-2009. Can Urol Assoc J 2014;8:259-267.
18.
Santos F, Zakaria AS, Kassouf W, Tanguay S, Aprikian A: High hospital and surgeon volume and its impact on overall survival after radical cystectomy among patients with bladder cancer in Quebec. World J Urol 2015;33:1323-1330.
19.
Martini T, Aziz A, Roghmann F, Rink M, Chun FK, Fisch M, et al: Prediction of locally advanced urothelial carcinoma of the bladder using clinical parameters before radical cystectomy - a prospective multicenter study. Urol Int 2015, Epub ahead of print.
20.
Berger I, Wehrberger C, Ponholzer A, Wolfgang M, Martini T, Breinl E, et al: Impact of the use of bowel for urinary diversion on perioperative complications and 90-day mortality in patients aged 75 years or older. Urol Int 2015;94:394-400.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.